PR Newswire
PHILADELPHIA
, July 10, 2025 /PRNewswire/ — Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders.
Year to date, shares of Amicus’ stock have declined over 32% in value, to trade at a current price of less than $7.00 per share.
The investigation seeks to determine whether Amicus and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.
Amicus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, or by clicking on the following link (or by copying and pasting the link into your browser):
https://kaskelalaw.com/case/amicus-therapeutics/
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-notice-kaskela-law-llc-announces-shareholder-investigation-of-amicus-therapeutics-inc-nasdaq-fold-and-encourages-long-term-fold-investors-to-contact-the-firm-302501839.html
SOURCE Kaskela Law LLC
